SCHEMBL3021350

SCHEMBL3021350

O=S(=O)(c1cccc(Br)c1)C1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
CACNA1G O43497 2/20 0.34
CACNA1H O95180 2/20 0.34
CACNA1I Q9P0X4 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
GPR6 P46095 1/20 0.33
HTR2A P28223 5/20 0.33
HTR2C P28335 4/20 0.33
KCNH2 Q12809 4/20 0.33
DRD2 P14416 2/20 0.32
DNM1L O00429 1/20 0.32
CTSS P25774 1/20 0.32
DCK P27707 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
PKM P14618 1/20 0.32
PKLR P30613 1/20 0.32
MBTD1 Q05BQ5 1/20 0.31
L3MBTL3 Q96JM7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003569 0.92 SOS1 (0.35) RAB9ANPC1SMN1; SMN2GPR6HTR2A
SCHEMBL3014287 0.92 RAB9A (0.33) RAB9ANPC1SMN1; SMN2GPR6HTR2A
SCHEMBL3003523 0.92 HTR2A (0.38) RAB9ANPC1SMN1; SMN2HTR2AHTR2C
SCHEMBL3008818 0.91 GPR6 (0.40) RAB9ANPC1CACNA1GCACNA1HCACNA1I
SCHEMBL3013066 0.90 RAB9A (0.39) RAB9ANPC1CACNA1GCACNA1HCACNA1I
SCHEMBL3015207 0.90 SMN1; SMN2 (0.36) RAB9ANPC1CACNA1GCACNA1HCACNA1I
SCHEMBL3008542 0.89 MAPT (0.36) RAB9ANPC1SMN1; SMN2HTR2AHTR2C
SCHEMBL3017825 0.89 GPR6 (0.35) RAB9ANPC1SMN1; SMN2GPR6HTR2A
SCHEMBL3007631 0.89 GPR6 (0.40) RAB9ANPC1SMN1; SMN2GPR6HTR2A
SCHEMBL3004812 0.88 RAB9A (0.36) RAB9ANPC1SMN1; SMN2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885NPC1 15/4885CACNA1G 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.